메뉴 건너뛰기




Volumn 9, Issue , 2014, Pages 1-25

Glioblastoma: From molecular pathology to targeted treatment

Author keywords

Acquired resistance; EGFRvIII; Glioblastoma; Intratumoral heterogeneity; MTOR; Signal transduction

Indexed keywords

ANIMAL; BRAIN TUMOR; DRUG RESISTANCE; GENETICS; GLIOBLASTOMA; HUMAN; MOLECULAR PATHOLOGY; PATHOLOGY; REVIEW;

EID: 84897019565     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130324     Document Type: Article
Times cited : (423)

References (161)
  • 1
    • 84859847164 scopus 로고    scopus 로고
    • Emerging insights into the molecular and cellular basis of glioblastoma
    • Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756-84
    • (2012) Genes Dev. , vol.26 , pp. 756-784
    • Dunn, G.P.1    Rinne, M.L.2    Wykosky, J.3    Genovese, G.4    Quayle, S.N.5
  • 2
    • 0035404677 scopus 로고    scopus 로고
    • Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups
    • Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. 2001. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology 3:152-58
    • (2001) Neuro-Oncology , vol.3 , pp. 152-158
    • Davis, F.G.1    Kupelian, V.2    Freels, S.3    McCarthy, B.4    Surawicz, T.5
  • 3
    • 84868023931 scopus 로고    scopus 로고
    • CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007
    • Dolecek TA, Propp JM, Stroup NE, Kruchko C. 2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Neuro-Oncology 4 (Suppl. 5):1-49
    • (2012) Neuro-Oncology , vol.4 , Issue.SUPPL. 5 , pp. 1-49
    • Dolecek, T.A.1    Propp, J.M.2    Stroup, N.E.3    Kruchko, C.4
  • 4
    • 77957067789 scopus 로고    scopus 로고
    • Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology
    • Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. 2010. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology 12:520-27
    • (2010) Neuro-Oncology , vol.12 , pp. 520-527
    • Porter, K.R.1    McCarthy, B.J.2    Freels, S.3    Kim, Y.4    Davis, F.G.5
  • 5
    • 20344407807 scopus 로고    scopus 로고
    • Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
    • Ohgaki H, Kleihues P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64:479-89
    • (2005) J. Neuropathol. Exp. Neurol. , vol.64 , pp. 479-489
    • Ohgaki, H.1    Kleihues, P.2
  • 6
    • 84860790212 scopus 로고    scopus 로고
    • Review. Molecular pathology in adult high-grade gliomas: From molecular diagnostics to target therapies
    • Masui K, Cloughesy TF, Mischel PS. 2012. Review. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol. 38:271-91
    • (2012) Neuropathol. Appl. Neurobiol. , vol.38 , pp. 271-291
    • Masui, K.1    Cloughesy, T.F.2    Mischel, P.S.3
  • 8
    • 84869878282 scopus 로고    scopus 로고
    • Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice
    • Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, et al. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338:1080-84
    • (2012) Science , vol.338 , pp. 1080-1084
    • Friedmann-Morvinski, D.1    Bushong, E.A.2    Ke, E.3    Soda, Y.4    Marumoto, T.5
  • 10
    • 84878362165 scopus 로고    scopus 로고
    • The next step in brain tumor classification "let us now praise famous men" or molecules?
    • Louis DN. 2012. The next step in brain tumor classification: "Let us now praise famous men" or molecules? Acta Neuropathol. 124:761-62
    • (2012) Acta Neuropathol. , vol.124 , pp. 761-762
    • Louis, D.N.1
  • 11
    • 84874091180 scopus 로고    scopus 로고
    • The definition of primary and secondary glioblastoma
    • Ohgaki H, Kleihues P. 2013. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19:764-72
    • (2013) Clin. Cancer Res. , vol.19 , pp. 764-772
    • Ohgaki, H.1    Kleihues, P.2
  • 12
    • 54549108740 scopus 로고    scopus 로고
    • Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    • Cancer Genome Atlas Res. Netw.
    • Cancer Genome Atlas Res. Netw. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
    • (2008) Nature , vol.455 , pp. 1061-1068
  • 13
    • 73649123907 scopus 로고    scopus 로고
    • Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
    • Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
    • (2010) Cancer Cell , vol.17 , pp. 98-110
    • Verhaak, R.G.1    Hoadley, K.A.2    Purdom, E.3    Wang, V.4    Qi, Y.5
  • 14
    • 52949127312 scopus 로고    scopus 로고
    • An integrated genomic analysis of human glioblastoma multiforme
    • Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
    • (2008) Science , vol.321 , pp. 1807-1812
    • Parsons, D.W.1    Jones, S.2    Zhang, X.3    Lin, J.C.4    Leary, R.J.5
  • 15
    • 38049100456 scopus 로고    scopus 로고
    • Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
    • Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104:20007-12
    • (2007) Proc. Natl. Acad. Sci. USA , vol.104 , pp. 20007-20012
    • Beroukhim, R.1    Getz, G.2    Nghiemphu, L.3    Barretina, J.4    Hsueh, T.5
  • 17
    • 33845926387 scopus 로고    scopus 로고
    • Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
    • Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. 2006. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3:e485
    • (2006) PLoS Med. , vol.3 , pp. e485
    • Lee, J.C.1    Vivanco, I.2    Beroukhim, R.3    Huang, J.H.4    Feng, W.L.5
  • 18
    • 84874645357 scopus 로고    scopus 로고
    • Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
    • Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, et al. 2013. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 45:253-61
    • (2013) Nat. Genet. , vol.45 , pp. 253-261
    • Morris, L.G.1    Kaufman, A.M.2    Gong, Y.3    Ramaswami, D.4    Walsh, L.A.5
  • 19
    • 84865805666 scopus 로고    scopus 로고
    • Transforming fusions of FGFR and TACC genes in human glioblastoma
    • Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, et al. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231-35
    • (2012) Science , vol.337 , pp. 1231-1235
    • Singh, D.1    Chan, J.M.2    Zoppoli, P.3    Niola, F.4    Sullivan, R.5
  • 20
    • 84873347374 scopus 로고    scopus 로고
    • The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
    • Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, et al. 2013. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Investig. 123:855-65
    • (2013) J. Clin. Investig. , vol.123 , pp. 855-865
    • Parker, B.C.1    Annala, M.J.2    Cogdell, D.E.3    Granberg, K.J.4    Sun, Y.5
  • 21
    • 33845807801 scopus 로고    scopus 로고
    • Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
    • Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, et al. 2006. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 66:11502-13
    • (2006) Cancer Res. , vol.66 , pp. 11502-11513
    • Maher, E.A.1    Brennan, C.2    Wen, P.Y.3    Durso, L.4    Ligon, K.L.5
  • 22
    • 31544467538 scopus 로고    scopus 로고
    • Distinct transcription profiles of primary and secondary glioblastoma subgroups
    • Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. 2006. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 66:159-67
    • (2006) Cancer Res. , vol.66 , pp. 159-167
    • Tso, C.L.1    Freije, W.A.2    Day, A.3    Chen, Z.4    Merriman, B.5
  • 23
    • 33644820339 scopus 로고    scopus 로고
    • Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
    • Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-73
    • (2006) Cancer Cell , vol.9 , pp. 157-173
    • Phillips, H.S.1    Kharbanda, S.2    Chen, R.3    Forrest, W.F.4    Soriano, R.H.5
  • 25
    • 77952108366 scopus 로고    scopus 로고
    • Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
    • Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-22
    • (2010) Cancer Cell , vol.17 , pp. 510-522
    • Noushmehr, H.1    Weisenberger, D.J.2    Diefes, K.3    Phillips, H.S.4    Pujara, K.5
  • 26
    • 84858796263 scopus 로고    scopus 로고
    • IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    • Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-83
    • (2012) Nature , vol.483 , pp. 479-483
    • Turcan, S.1    Rohle, D.2    Goenka, A.3    Walsh, L.A.4    Fang, F.5
  • 27
    • 84862777348 scopus 로고    scopus 로고
    • Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
    • Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-31
    • (2012) Nature , vol.482 , pp. 226-231
    • Schwartzentruber, J.1    Korshunov, A.2    Liu, X.Y.3    Jones, D.T.4    Pfaff, E.5
  • 28
    • 84867606428 scopus 로고    scopus 로고
    • Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma
    • SturmD, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, et al. 2012. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-37
    • (2012) Cancer Cell , vol.22 , pp. 425-437
    • Sturm, D.1    Witt, H.2    Hovestadt, V.3    Khuong-Quang, D.A.4    Jones, D.T.5
  • 29
    • 75149195336 scopus 로고    scopus 로고
    • The transcriptional network for mesenchymal transformation of brain tumours
    • Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, et al. 2010. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-25
    • (2010) Nature , vol.463 , pp. 318-325
    • Carro, M.S.1    Lim, W.K.2    Alvarez, M.J.3    Bollo, R.J.4    Zhao, X.5
  • 30
    • 80054689794 scopus 로고    scopus 로고
    • An extensivemicroRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma
    • Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, et al. 2011. An extensivemicroRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147:370-81
    • (2011) Cell , vol.147 , pp. 370-381
    • Sumazin, P.1    Yang, X.2    Chiu, H.S.3    Chung, W.J.4    Iyer, A.5
  • 31
    • 84866248155 scopus 로고    scopus 로고
    • MicroRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma
    • Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, et al. 2012. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov. 2:736-49
    • (2012) Cancer Discov. , vol.2 , pp. 736-749
    • Genovese, G.1    Ergun, A.2    Shukla, S.A.3    Campos, B.4    Hanna, J.5
  • 32
    • 70849122697 scopus 로고    scopus 로고
    • Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations
    • Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. 2009. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752
    • (2009) PLoS ONE , vol.4 , pp. e7752
    • Brennan, C.1    Momota, H.2    Hambardzumyan, D.3    Ozawa, T.4    Tandon, A.5
  • 33
    • 84873336376 scopus 로고    scopus 로고
    • Multiple functions of a glioblastoma fusion oncogene
    • Babic I, Mischel PS. 2013. Multiple functions of a glioblastoma fusion oncogene. J. Clin. Investig. 123:548-51
    • (2013) J. Clin. Investig. , vol.123 , pp. 548-551
    • Babic, I.1    Mischel, P.S.2
  • 34
    • 79952509861 scopus 로고    scopus 로고
    • Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain
    • Chow LM, Endersby R, Zhu X, Rankin S, Qu C, et al. 2011. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305-16
    • (2011) Cancer Cell , vol.19 , pp. 305-316
    • Chow, L.M.1    Endersby, R.2    Zhu, X.3    Rankin, S.4    Qu, C.5
  • 35
    • 38949117993 scopus 로고    scopus 로고
    • Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples
    • Yoshimoto K, Dang J, Zhu S, NathansonD, Huang T, et al. 2008. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin. Cancer Res. 14:488-93
    • (2008) Clin. Cancer Res. , vol.14 , pp. 488-493
    • Yoshimoto, K.1    Dang, J.2    Zhu, S.3    Nathanson, D.4    Huang, T.5
  • 36
    • 73949083511 scopus 로고    scopus 로고
    • Oncogenic EGFR signaling networks in glioma
    • Huang PH, Xu AM, White FM. 2009. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2:re6
    • (2009) Sci. Signal. , vol.2 , pp. re6
    • Huang, P.H.1    Xu, A.M.2    White, F.M.3
  • 37
    • 84861760527 scopus 로고    scopus 로고
    • Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
    • Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, et al. 2012. Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2:458-71
    • (2012) Cancer Discov. , vol.2 , pp. 458-471
    • Vivanco, I.1    Robins, H.I.2    Rohle, D.3    Campos, C.4    Grommes, C.5
  • 38
    • 77249101567 scopus 로고    scopus 로고
    • Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence
    • Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. 2010. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc. Natl. Acad. Sci. USA 107:2616-21
    • (2010) Proc. Natl. Acad. Sci. USA , vol.107 , pp. 2616-2621
    • Mukasa, A.1    Wykosky, J.2    Ligon, K.L.3    Chin, L.4    Cavenee, W.K.5    Furnari, F.6
  • 39
    • 84864400820 scopus 로고    scopus 로고
    • Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma
    • Kesavabhotla K, Schlaff CD, Shin B, Mubita L, Kaplan R, et al. 2012. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J. Exp. Ther. Oncol. 10:71-81
    • (2012) J. Exp. Ther. Oncol. , vol.10 , pp. 71-81
    • Kesavabhotla, K.1    Schlaff, C.D.2    Shin, B.3    Mubita, L.4    Kaplan, R.5
  • 40
    • 78049306732 scopus 로고    scopus 로고
    • Safety and efficacy of erlotinib in first-relapse glioblastoma: A phase II open-label study
    • Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, et al. 2010. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology 12:1061-70
    • (2010) Neuro-Oncology , vol.12 , pp. 1061-1070
    • Yung, W.K.1    Vredenburgh, J.J.2    Cloughesy, T.F.3    Nghiemphu, P.4    Klencke, B.5
  • 41
    • 75749122223 scopus 로고    scopus 로고
    • A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
    • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, et al. 2010. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 12:95-103
    • (2010) Neuro-Oncology , vol.12 , pp. 95-103
    • Raizer, J.J.1    Abrey, L.E.2    Lassman, A.B.3    Chang, S.M.4    Lamborn, K.R.5
  • 42
    • 34247218483 scopus 로고    scopus 로고
    • Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro- Oncologia (GICNO
    • Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, et al. 2007. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro- Oncologia (GICNO). Br. J. Cancer 96:1047-51
    • (2007) Br. J. Cancer , vol.96 , pp. 1047-1051
    • Franceschi, E.1    Cavallo, G.2    Lonardi, S.3    Magrini, E.4    Tosoni, A.5
  • 43
    • 62449150719 scopus 로고    scopus 로고
    • Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
    • van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, et al. 2009. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27:1268-74
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1268-1274
    • Van Den Bent, M.J.1    Brandes, A.A.2    Rampling, R.3    Kouwenhoven, M.C.4    Kros, J.M.5
  • 44
    • 27744606737 scopus 로고    scopus 로고
    • Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
    • Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353:2012-24
    • (2005) N. Engl. J. Med. , vol.353 , pp. 2012-2024
    • Mellinghoff, I.K.1    Wang, M.Y.2    Vivanco, I.3    Haas-Kogan, D.A.4    Zhu, S.5
  • 45
    • 84865542459 scopus 로고    scopus 로고
    • Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
    • Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, et al. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. USA 109:14164-69
    • (2012) Proc. Natl. Acad. Sci. USA , vol.109 , pp. 14164-14169
    • Fenton, T.R.1    Nathanson, D.2    Ponte De Albuquerque, C.3    Kuga, D.4    Iwanami, A.5
  • 46
    • 77950891445 scopus 로고    scopus 로고
    • The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation
    • Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, et al. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. USA 107:6459-64
    • (2010) Proc. Natl. Acad. Sci. USA , vol.107 , pp. 6459-6464
    • Vivanco, I.1    Rohle, D.2    Versele, M.3    Iwanami, A.4    Kuga, D.5
  • 47
    • 35348822482 scopus 로고    scopus 로고
    • Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
    • Stommel JM, Kimmelman AC, YingH, Nabioullin R, Ponugoti AH, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-90
    • (2007) Science , vol.318 , pp. 287-290
    • Stommel, J.M.1    Kimmelman, A.C.2    Ying, H.3    Nabioullin, R.4    Ponugoti, A.H.5
  • 48
    • 83455176258 scopus 로고    scopus 로고
    • Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma
    • Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-17
    • (2011) Cancer Cell , vol.20 , pp. 810-817
    • Snuderl, M.1    Fazlollahi, L.2    Le, L.P.3    Nitta, M.4    Zhelyazkova, B.H.5
  • 49
    • 84857397985 scopus 로고    scopus 로고
    • Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
    • Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, et al. 2012. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 109:3041-46
    • (2012) Proc. Natl. Acad. Sci. USA , vol.109 , pp. 3041-3046
    • Szerlip, N.J.1    Pedraza, A.2    Chakravarty, D.3    Azim, M.4    McGuire, J.5
  • 50
    • 84877593565 scopus 로고    scopus 로고
    • De-repression ofPDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients
    • AkhavanD, Pourzia AL, Nourian AA, WilliamsKJ, NathansonD, et al. 2013. De-repression ofPDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 3:534-47
    • (2013) Cancer Discov. , vol.3 , pp. 534-547
    • Akhavan, D.1    Pourzia, A.L.2    Nourian, A.A.3    Williams, K.J.4    Nathanson, D.5
  • 51
    • 84861760526 scopus 로고    scopus 로고
    • Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers
    • Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, et al. 2012. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov. 2:450-57
    • (2012) Cancer Discov. , vol.2 , pp. 450-457
    • Barkovich, K.J.1    Hariono, S.2    Garske, A.L.3    Zhang, J.4    Blair, J.A.5
  • 53
    • 18244371651 scopus 로고    scopus 로고
    • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    • PaoW, Miller VA, Politi KA, Riely GJ, Somwar R, et al. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73
    • (2005) PLoS Med. , vol.2 , pp. e73
    • Pao, W.1    Miller, V.A.2    Politi, K.A.3    Riely, G.J.4    Somwar, R.5
  • 54
    • 33745260930 scopus 로고    scopus 로고
    • AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling
    • Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. 2006. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 66:5618-23
    • (2006) Cancer Res. , vol.66 , pp. 5618-5623
    • Riemenschneider, M.J.1    Betensky, R.A.2    Pasedag, S.M.3    Louis, D.N.4
  • 55
    • 0038615946 scopus 로고    scopus 로고
    • Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
    • Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63:2742-46
    • (2003) Cancer Res. , vol.63 , pp. 2742-2746
    • Choe, G.1    Horvath, S.2    Cloughesy, T.F.3    Crosby, K.4    Seligson, D.5
  • 56
    • 33744489071 scopus 로고    scopus 로고
    • Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays
    • Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, et al. 2006. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964-71
    • (2006) Proteomics , vol.6 , pp. 2964-2971
    • Jiang, R.1    Mircean, C.2    Shmulevich, I.3    Cogdell, D.4    Jia, Y.5
  • 57
    • 84859778293 scopus 로고    scopus 로고
    • MTOR signaling in growth control and disease
    • Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
    • (2012) Cell , vol.149 , pp. 274-293
    • Laplante, M.1    Sabatini, D.M.2
  • 59
    • 33750351403 scopus 로고    scopus 로고
    • Signal transduction: Protein synthesis and oncogenesis meet again
    • Sonenberg N, Pause A. 2006. Signal transduction: Protein synthesis and oncogenesis meet again. Science 314:428-29
    • (2006) Science , vol.314 , pp. 428-429
    • Sonenberg, N.1    Pause, A.2
  • 60
    • 79955779584 scopus 로고    scopus 로고
    • MTOR links oncogenic signaling to tumor cell metabolism
    • Yecies JL, Manning BD. 2011. mTOR links oncogenic signaling to tumor cell metabolism. J. Mol. Med. 89:221-28
    • (2011) J. Mol. Med. , vol.89 , pp. 221-228
    • Yecies, J.L.1    Manning, B.D.2
  • 61
    • 32944457518 scopus 로고    scopus 로고
    • MTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • OReilly KE, Rojo F, She QB, Solit D, Mills GB, et al. 2006.mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-8
    • (2006) Cancer Res. , vol.66 , pp. 1500-1508
    • Oreilly, K.E.1    Rojo, F.2    She, Q.B.3    Solit, D.4    Mills, G.B.5
  • 63
    • 69149097363 scopus 로고    scopus 로고
    • The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
    • Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, et al. 2009. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. USA 106:12932-37
    • (2009) Proc. Natl. Acad. Sci. USA , vol.106 , pp. 12932-12937
    • Guo, D.1    Hildebrandt, I.J.2    Prins, R.M.3    Soto, H.4    Mazzotta, M.M.5
  • 64
    • 33846164111 scopus 로고    scopus 로고
    • Renal-cell carcinoma-molecular pathways and therapies
    • Brugarolas J. 2007. Renal-cell carcinoma-molecular pathways and therapies. N. Engl. J.Med. 356:185-87
    • (2007) N. Engl. J.Med. , vol.356 , pp. 185-187
    • Brugarolas, J.1
  • 65
    • 2942724235 scopus 로고    scopus 로고
    • MTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic andHIF-1-dependent pathways
    • Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. 2004. mTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic andHIF-1-dependent pathways. Nat. Med. 10:594-601
    • (2004) Nat. Med. , vol.10 , pp. 594-601
    • Majumder, P.K.1    Febbo, P.G.2    Bikoff, R.3    Berger, R.4    Xue, Q.5
  • 66
    • 77955483125 scopus 로고    scopus 로고
    • Activation of a metabolic gene regulatory network downstream of mTOR complex 1
    • Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39:171-83
    • (2010) Mol. Cell , vol.39 , pp. 171-183
    • Duvel, K.1    Yecies, J.L.2    Menon, S.3    Raman, P.4    Lipovsky, A.I.5
  • 67
    • 50049116472 scopus 로고    scopus 로고
    • SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
    • Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, et al. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224-36
    • (2008) Cell Metab. , vol.8 , pp. 224-236
    • Porstmann, T.1    Santos, C.R.2    Griffiths, B.3    Cully, M.4    Wu, M.5
  • 68
    • 79961165137 scopus 로고    scopus 로고
    • MTOR complex 1 regulates lipin 1 localization to control the SREBP pathway
    • Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, et al. 2011. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146:408-20
    • (2011) Cell , vol.146 , pp. 408-420
    • Peterson, T.R.1    Sengupta, S.S.2    Harris, T.E.3    Carmack, A.E.4    Kang, S.A.5
  • 69
    • 79251587803 scopus 로고    scopus 로고
    • Phosphorylation ofULK1 (hATG1) by AMP-Activated protein kinase connects energy sensing to mitophagy
    • EganDF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, et al. 2011. Phosphorylation ofULK1 (hATG1) by AMP-Activated protein kinase connects energy sensing to mitophagy. Science 331:456-61
    • (2011) Science , vol.331 , pp. 456-461
    • Egan, D.F.1    Shackelford, D.B.2    Mihaylova, M.M.3    Gelino, S.4    Kohnz, R.A.5
  • 70
    • 13844312400 scopus 로고    scopus 로고
    • Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
    • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-101
    • (2005) Science , vol.307 , pp. 1098-1101
    • Sarbassov, D.D.1    Guertin, D.A.2    Ali, S.M.3    Sabatini, D.M.4
  • 71
    • 84860816141 scopus 로고    scopus 로고
    • Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance
    • Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, et al. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 1:524-38
    • (2011) Cancer Discov. , vol.1 , pp. 524-538
    • Tanaka, K.1    Babic, I.2    Nathanson, D.3    Akhavan, D.4    Guo, D.5
  • 72
    • 38849208347 scopus 로고    scopus 로고
    • Antitumor activity of rapamycin in a Phase i trial for patients with recurrent PTEN-deficient glioblastoma
    • Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. 2008. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5:e8
    • (2008) PLoS Med. , vol.5 , pp. e8
    • Cloughesy, T.F.1    Yoshimoto, K.2    Nghiemphu, P.3    Brown, K.4    Dang, J.5
  • 73
    • 56249147509 scopus 로고    scopus 로고
    • Rapamycin differentially inhibits S6Ks and 4EBP1 tomediate cell-type-specific repression of mRNA translation
    • Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4EBP1 tomediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 105:17414-19
    • (2008) Proc. Natl. Acad. Sci. USA , vol.105 , pp. 17414-17419
    • Choo, A.Y.1    Yoon, S.O.2    Kim, S.G.3    Roux, P.P.4    Blenis, J.5
  • 74
    • 61449245596 scopus 로고    scopus 로고
    • A Drosophila model for EGFR-Ras and PI3Kdependent human glioma
    • Read RD, Cavenee WK, Furnari FB, Thomas JB. 2009. A Drosophila model for EGFR-Ras and PI3Kdependent human glioma. PLoS Genet. 5:e1000374
    • (2009) PLoS Genet. , vol.5 , pp. e1000374
    • Read, R.D.1    Cavenee, W.K.2    Furnari, F.B.3    Thomas, J.B.4
  • 75
    • 84867539301 scopus 로고    scopus 로고
    • Conditional astroglial rictor overexpression induces malignant glioma in mice
    • Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, et al. 2012. Conditional astroglial rictor overexpression induces malignant glioma in mice. PLoS ONE 7:e47741
    • (2012) PLoS ONE , vol.7 , pp. e47741
    • Bashir, T.1    Cloninger, C.2    Artinian, N.3    Anderson, L.4    Bernath, A.5
  • 76
    • 37549048521 scopus 로고    scopus 로고
    • MTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor
    • Masri J, Bernath A, Martin J, Jo OD, Vartanian R, et al. 2007. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67:11712-20
    • (2007) Cancer Res. , vol.67 , pp. 11712-11720
    • Masri, J.1    Bernath, A.2    Martin, J.3    Jo, O.D.4    Vartanian, R.5
  • 77
    • 0032510679 scopus 로고    scopus 로고
    • Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
    • Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. 1998. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95:5724-29
    • (1998) Proc. Natl. Acad. Sci. USA , vol.95 , pp. 5724-5729
    • Nagane, M.1    Levitzki, A.2    Gazit, A.3    Cavenee, W.K.4    Huang, H.J.5
  • 78
    • 78149475478 scopus 로고    scopus 로고
    • Akt and autophagy cooperate to promote survival of drug-resistant glioma
    • Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. 2010. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 3:ra81
    • (2010) Sci. Signal. , vol.3 , pp. ra81
    • Fan, Q.W.1    Cheng, C.2    Hackett, C.3    Feldman, M.4    Houseman, B.T.5
  • 80
    • 33747488399 scopus 로고    scopus 로고
    • PML inhibits HIF-1αtranslation and neoangiogenesis through repression of mTOR
    • Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, et al. 2006. PML inhibits HIF-1αtranslation and neoangiogenesis through repression of mTOR. Nature 442:779-85
    • (2006) Nature , vol.442 , pp. 779-785
    • Bernardi, R.1    Guernah, I.2    Jin, D.3    Grisendi, S.4    Alimonti, A.5
  • 81
    • 84875009534 scopus 로고    scopus 로고
    • PMLmediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
    • Iwanami A, Gini B, Zanca C, MatsutaniT, Assuncao A, et al. 2013.PMLmediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc. Natl. Acad. Sci. USA 110:4339-44
    • (2013) Proc. Natl. Acad. Sci. USA , vol.110 , pp. 4339-4344
    • Iwanami, A.1    Gini, B.2    Zanca, C.3    Matsutani, T.4    Assuncao, A.5
  • 82
    • 70349653793 scopus 로고    scopus 로고
    • IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas
    • Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 15:6002-7
    • (2009) Clin. Cancer Res. , vol.15 , pp. 6002-6007
    • Nobusawa, S.1    Watanabe, T.2    Kleihues, P.3    Ohgaki, H.4
  • 84
    • 72049125350 scopus 로고    scopus 로고
    • Cancer-Associated IDH1mutations produce 2-hydroxyglutarate
    • Dang L, WhiteDW, Gross S, Bennett BD, Bittinger MA, et al. 2009. Cancer-Associated IDH1mutations produce 2-hydroxyglutarate. Nature 462:739-44
    • (2009) Nature , vol.462 , pp. 739-744
    • Dang, L.1    White, D.W.2    Gross, S.3    Bennett, B.D.4    Bittinger, M.A.5
  • 85
    • 78650019179 scopus 로고    scopus 로고
    • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
    • Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
    • (2010) Cancer Cell , vol.18 , pp. 553-567
    • Figueroa, M.E.1    Abdel-Wahab, O.2    Lu, C.3    Ward, P.S.4    Patel, J.5
  • 86
    • 77649305610 scopus 로고    scopus 로고
    • The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate
    • Ward PS, Patel J, Wise DR, Abdel-WahabO, Bennett BD, et al. 2010. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-34
    • (2010) Cancer Cell , vol.17 , pp. 225-234
    • Ward, P.S.1    Patel, J.2    Wise, D.R.3    Abdel-Wahab, O.4    Bennett, B.D.5
  • 87
    • 84862776918 scopus 로고    scopus 로고
    • Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
    • Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, et al. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-88
    • (2012) Nature , vol.483 , pp. 484-488
    • Koivunen, P.1    Lee, S.2    Duncan, C.G.3    Lopez, G.4    Lu, G.5
  • 88
    • 83355163405 scopus 로고    scopus 로고
    • Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
    • LaiA, Kharbanda S, PopeWB, Tran A, Solis OE, et al. 2011. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 9:4482-90
    • (2011) J. Clin. Oncol. , vol.9 , pp. 4482-4490
    • Lai, A.1    Kharbanda, S.2    Pope, W.B.3    Tran, A.4    Solis, O.E.5
  • 89
    • 84858796262 scopus 로고    scopus 로고
    • IDH mutation impairs histone demethylation and results in a block to cell differentiation
    • Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-78
    • (2012) Nature , vol.483 , pp. 474-478
    • Lu, C.1    Ward, P.S.2    Kapoor, G.S.3    Rohle, D.4    Turcan, S.5
  • 90
    • 60949083613 scopus 로고    scopus 로고
    • The molecular determinants of de novo nucleotide biosynthesis in cancer cells
    • Tong X, Zhao F, Thompson CB. 2009. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19:32-37
    • (2009) Curr. Opin. Genet. Dev. , vol.19 , pp. 32-37
    • Tong, X.1    Zhao, F.2    Thompson, C.B.3
  • 91
    • 84862016091 scopus 로고    scopus 로고
    • Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo
    • Marin-Valencia I, Yang C, MashimoT, Cho S, Baek H, et al. 2012. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15:827-37
    • (2012) Cell Metab. , vol.15 , pp. 827-837
    • Marin-Valencia, I.1    Yang, C.2    Mashimo, T.3    Cho, S.4    Baek, H.5
  • 92
    • 40749163248 scopus 로고    scopus 로고
    • TheM2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
    • Christofk HR, VanderHeidenMG, HarrisMH, Ramanathan A, Gerszten RE, et al. 2008. TheM2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-33
    • (2008) Nature , vol.452 , pp. 230-233
    • Christofk, H.R.1    Vanderheiden, M.G.2    Harris, M.H.3    Ramanathan, A.4    Gerszten, R.E.5
  • 94
    • 66249108601 scopus 로고    scopus 로고
    • Understanding the Warburg effect: The metabolic requirements of cell proliferation
    • Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33
    • (2009) Science , vol.324 , pp. 1029-1033
    • Vander Heiden, M.G.1    Cantley, L.C.2    Thompson, C.B.3
  • 95
    • 75149150660 scopus 로고    scopus 로고
    • HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
    • David CJ, Chen M, Assanah M, Canoll P, Manley JL. 2010. hnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364-68
    • (2010) Nature , vol.463 , pp. 364-368
    • David, C.J.1    Chen, M.2    Assanah, M.3    Canoll, P.4    Manley, J.L.5
  • 96
    • 84856189114 scopus 로고    scopus 로고
    • Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis
    • Lu Z. 2012. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer 31:5-7
    • (2012) Chin. J. Cancer , vol.31 , pp. 5-7
    • Lu, Z.1
  • 97
    • 84870885534 scopus 로고    scopus 로고
    • EGFR-induced and PKC? Monoubiquitylation- dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis
    • Yang W, Xia Y, Cao Y, Zheng Y, Bu W, et al. 2012. EGFR-induced and PKC? monoubiquitylation- dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 48:771-84
    • (2012) Mol. Cell , vol.48 , pp. 771-784
    • Yang, W.1    Xia, Y.2    Cao, Y.3    Zheng, Y.4    Bu, W.5
  • 98
    • 82555170271 scopus 로고    scopus 로고
    • Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
    • Yang W, Xia Y, Ji H, Zheng Y, Liang J, et al. 2011. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480:118-22
    • (2011) Nature , vol.480 , pp. 118-122
    • Yang, W.1    Xia, Y.2    Ji, H.3    Zheng, Y.4    Liang, J.5
  • 99
    • 84865266173 scopus 로고    scopus 로고
    • PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis
    • Yang W, Xia Y, Hawke D, Li X, Liang J, et al. 2012. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150:685-96
    • (2012) Cell , vol.150 , pp. 685-696
    • Yang, W.1    Xia, Y.2    Hawke, D.3    Li, X.4    Liang, J.5
  • 100
    • 84870598190 scopus 로고    scopus 로고
    • ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
    • Yang W, Zheng Y, Xia Y, Ji H, Chen X, et al. 2012. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14:1295-304
    • (2012) Nat. Cell Biol. , vol.14 , pp. 1295-1304
    • Yang, W.1    Zheng, Y.2    Xia, Y.3    Ji, H.4    Chen, X.5
  • 101
    • 84878800044 scopus 로고    scopus 로고
    • EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer
    • Babic I, Anderson ES, Tanaka K, Guo D, Masui K, et al. 2013. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 17:1000-8
    • (2013) Cell Metab. , vol.17 , pp. 1000-1008
    • Babic, I.1    Anderson, E.S.2    Tanaka, K.3    Guo, D.4    Masui, K.5
  • 102
    • 84859752151 scopus 로고    scopus 로고
    • The music of lipids: How lipid composition orchestrates cellular behaviour
    • Schug ZT, Frezza C, Galbraith LC, Gottlieb E. 2012. The music of lipids: how lipid composition orchestrates cellular behaviour. Acta Oncol. 51:301-10
    • (2012) Acta Oncol. , vol.51 , pp. 301-310
    • Schug, Z.T.1    Frezza, C.2    Galbraith, L.C.3    Gottlieb, E.4
  • 103
    • 84858604270 scopus 로고    scopus 로고
    • Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate
    • Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308
    • (2012) Cancer Cell , vol.21 , pp. 297-308
    • Ward, P.S.1    Thompson, C.B.2
  • 104
    • 77649216053 scopus 로고    scopus 로고
    • EGFR signaling through an Akt-SREBP- 1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
    • Guo D, Prins RM, Dang J, Kuga D, Iwanami A, et al. 2009. EGFR signaling through an Akt-SREBP- 1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal. 2:ra82
    • (2009) Sci. Signal. , vol.2 , pp. ra82
    • Guo, D.1    Prins, R.M.2    Dang, J.3    Kuga, D.4    Iwanami, A.5
  • 105
    • 0030941803 scopus 로고    scopus 로고
    • The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
    • Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-40
    • (1997) Cell , vol.89 , pp. 331-340
    • Brown, M.S.1    Goldstein, J.L.2
  • 106
    • 84877961669 scopus 로고    scopus 로고
    • Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth
    • Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, et al. 2013. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Camcer Metab. 1:3
    • (2013) Camcer Metab. , vol.1 , pp. 3
    • Griffiths, B.1    Lewis, C.A.2    Bensaad, K.3    Ros, S.4    Zhang, Q.5
  • 107
    • 84877731629 scopus 로고    scopus 로고
    • An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity
    • Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, et al. 2013. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 73:2850-62
    • (2013) Cancer Res. , vol.73 , pp. 2850-2862
    • Williams, K.J.1    Argus, J.P.2    Zhu, Y.3    Wilks, M.Q.4    Marbois, B.N.5
  • 108
    • 84861101004 scopus 로고    scopus 로고
    • AnLXRagonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway
    • GuoD, Reinitz F, YoussefM, HongC, Nathanson D, et al. 2011. AnLXRagonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1:442-56
    • (2011) Cancer Discov. , vol.1 , pp. 442-456
    • Guo, D.1    Reinitz, F.2    Youssef, M.3    Hong, C.4    Nathanson, D.5
  • 109
    • 84856004321 scopus 로고    scopus 로고
    • Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
    • Shi Q, Qin L, Wei W, Geng F, Fan R, et al. 2012. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc. Natl. Acad. Sci. USA 109:419-24
    • (2012) Proc. Natl. Acad. Sci. USA , vol.109 , pp. 419-424
    • Shi, Q.1    Qin, L.2    Wei, W.3    Geng, F.4    Fan, R.5
  • 111
    • 79958849271 scopus 로고    scopus 로고
    • Heterogeneity maintenance in glioblastoma: A social network
    • Bonavia R, Inda MM, Cavenee WK, Furnari FB. 2011. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71:4055-60
    • (2011) Cancer Res. , vol.71 , pp. 4055-4060
    • Bonavia, R.1    Inda, M.M.2    Cavenee, W.K.3    Furnari, F.B.4
  • 112
    • 0036737914 scopus 로고    scopus 로고
    • Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro
    • Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. 2002. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206
    • (2002) Glia , vol.39 , pp. 193-206
    • Ignatova, T.N.1    Kukekov, V.G.2    Laywell, E.D.3    Suslov, O.N.4    Vrionis, F.D.5    Steindler, D.A.6
  • 116
    • 65349115320 scopus 로고    scopus 로고
    • SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma
    • Son MJ, Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma. Cell Stem Cell 4:440-52
    • (2009) Cell Stem Cell , vol.4 , pp. 440-452
    • Son, M.J.1    Woolard, K.2    Nam, D.H.3    Lee, J.4    Fine, H.A.5
  • 117
    • 84861789402 scopus 로고    scopus 로고
    • Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity
    • Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, et al. 2012. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 26:1247-62
    • (2012) Genes Dev. , vol.26 , pp. 1247-1262
    • Kim, Y.1    Kim, E.2    Wu, Q.3    Guryanova, O.4    Hitomi, M.5
  • 118
    • 79959969874 scopus 로고    scopus 로고
    • Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase 2
    • Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, et al. 2011. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase 2. Cell 146:53-66
    • (2011) Cell , vol.146 , pp. 53-66
    • Eyler, C.E.1    Wu, Q.2    Yan, K.3    Macswords, J.M.4    Chandler-Militello, D.5
  • 119
    • 75349091751 scopus 로고    scopus 로고
    • Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells
    • CharlesN, OzawaT, SquatritoM, Bleau AM, BrennanCW, et al. 2010. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6:141-52
    • (2010) Cell Stem Cell , vol.6 , pp. 141-152
    • Charles, N.1    Ozawa, T.2    Squatrito, M.3    Bleau, A.M.4    Brennan, C.W.5
  • 120
    • 80053058993 scopus 로고    scopus 로고
    • Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells
    • Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, et al. 2011. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS ONE 6:e24807
    • (2011) PLoS ONE , vol.6 , pp. e24807
    • Lathia, J.D.1    Gallagher, J.2    Myers, J.T.3    Li, M.4    Vasanji, A.5
  • 121
    • 33845317573 scopus 로고    scopus 로고
    • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    • Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-60
    • (2006) Nature , vol.444 , pp. 756-760
    • Bao, S.1    Wu, Q.2    McLendon, R.E.3    Hao, Y.4    Shi, Q.5
  • 122
    • 84865203983 scopus 로고    scopus 로고
    • A restricted cell population propagates glioblastoma growth after chemotherapy
    • Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-26
    • (2012) Nature , vol.488 , pp. 522-526
    • Chen, J.1    Li, Y.2    Yu, T.S.3    McKay, R.M.4    Burns, D.K.5
  • 124
    • 79955031521 scopus 로고    scopus 로고
    • Seeing is believing: Are cancer stem cells the Loch Ness monster of tumor biology?
    • Lathia JD, Venere M, Rao MS, Rich JN. 2011. Seeing is believing: Are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev. 7:227-37
    • (2011) Stem Cell Rev. , vol.7 , pp. 227-237
    • Lathia, J.D.1    Venere, M.2    Rao, M.S.3    Rich, J.N.4
  • 125
    • 19044397160 scopus 로고    scopus 로고
    • Epidermal growth factor receptor and INK4A/ARF: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis
    • Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, et al. 2002. Epidermal growth factor receptor and INK4A/ARF: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-77
    • (2002) Cancer Cell , vol.1 , pp. 269-277
    • Bachoo, R.M.1    Maher, E.A.2    Ligon, K.L.3    Sharpless, N.E.4    Chan, S.S.5
  • 126
    • 23644443053 scopus 로고    scopus 로고
    • Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma
    • Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, et al. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-30
    • (2005) Cancer Cell , vol.8 , pp. 119-130
    • Zhu, Y.1    Guignard, F.2    Zhao, D.3    Liu, L.4    Burns, D.K.5
  • 127
    • 57849109837 scopus 로고    scopus 로고
    • Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model
    • Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, et al. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45-56
    • (2009) Cancer Cell , vol.15 , pp. 45-56
    • Alcantara Llaguno, S.1    Chen, J.2    Kwon, C.H.3    Jackson, E.L.4    Li, Y.5
  • 128
    • 79953766940 scopus 로고    scopus 로고
    • Tumour evolution inferred by single-cell sequencing
    • NavinN, Kendall J, Troge J, Andrews P, Rodgers L, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:90-94
    • (2011) Nature , vol.472 , pp. 90-94
    • Navin, N.1    Kendall, J.2    Troge, J.3    Andrews, P.4    Rodgers, L.5
  • 129
    • 84863393080 scopus 로고    scopus 로고
    • Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    • GerlingerM, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-92
    • (2012) N. Engl. J. Med. , vol.366 , pp. 883-892
    • Gerlinger, M.1    Rowan, A.J.2    Horswell, S.3    Larkin, J.4    Endesfelder, D.5
  • 131
    • 84856013431 scopus 로고    scopus 로고
    • Clonal evolution in cancer
    • Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481:306-13
    • (2012) Nature , vol.481 , pp. 306-313
    • Greaves, M.1    Maley, C.C.2
  • 132
    • 66249136447 scopus 로고    scopus 로고
    • Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
    • Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. 2009. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459:428-32
    • (2009) Nature , vol.459 , pp. 428-432
    • Spencer, S.L.1    Gaudet, S.2    Albeck, J.G.3    Burke, J.M.4    Sorger, P.K.5
  • 133
    • 77955911497 scopus 로고    scopus 로고
    • Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
    • Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. 2010. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24:1731-45
    • (2010) Genes Dev. , vol.24 , pp. 1731-1745
    • Inda, M.M.1    Bonavia, R.2    Mukasa, A.3    Narita, Y.4    Sah, D.W.5
  • 134
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • StraussmanR, MorikawaT, SheeK, Barzily-RokniM, Qian ZR, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4
    • (2012) Nature , vol.487 , pp. 500-504
    • Straussman, R.1    Morikawa, T.2    Shee, K.3    Barzily-Rokni, M.4    Qian, Z.R.5
  • 135
    • 84857666591 scopus 로고    scopus 로고
    • Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment
    • Katz AM, Amankulor NM, Pitter K, Helmy K, Squatrito M, Holland EC. 2012. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS ONE 7:e32453
    • (2012) PLoS ONE , vol.7 , pp. e32453
    • Katz, A.M.1    Amankulor, N.M.2    Pitter, K.3    Helmy, K.4    Squatrito, M.5    Holland, E.C.6
  • 137
    • 84866510711 scopus 로고    scopus 로고
    • Mechanisms of glioma-Associated neovascularization
    • Hardee ME, Zagzag D. 2012. Mechanisms of glioma-Associated neovascularization. Am. J. Pathol. 181:1126-41
    • (2012) Am. J. Pathol. , vol.181 , pp. 1126-1141
    • Hardee, M.E.1    Zagzag, D.2
  • 138
    • 78650153633 scopus 로고    scopus 로고
    • Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
    • Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, et al. 2010. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824-28
    • (2010) Nature , vol.468 , pp. 824-828
    • Ricci-Vitiani, L.1    Pallini, R.2    Biffoni, M.3    Todaro, M.4    Invernici, G.5
  • 139
  • 141
    • 84875755046 scopus 로고    scopus 로고
    • Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth
    • Cheng L, Huang Z, Zhu W, Wu Q, Donnola S, et al. 2013. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139-52
    • (2013) Cell , vol.153 , pp. 139-152
    • Cheng, L.1    Huang, Z.2    Zhu, W.3    Wu, Q.4    Donnola, S.5
  • 142
    • 59949083263 scopus 로고    scopus 로고
    • Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
    • Kreisl TN, Kim L, Moore K, Duic P, Royce C, et al. 2009. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27:740-45
    • (2009) J. Clin. Oncol. , vol.27 , pp. 740-745
    • Kreisl, T.N.1    Kim, L.2    Moore, K.3    Duic, P.4    Royce, C.5
  • 143
    • 70350461699 scopus 로고    scopus 로고
    • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
    • Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27:4733-40
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4733-4740
    • Friedman, H.S.1    Prados, M.D.2    Wen, P.Y.3    Mikkelsen, T.4    Schiff, D.5
  • 144
    • 84871960565 scopus 로고    scopus 로고
    • Standards of care for treatment of recurrent glioblastoma: Are we there yet?
    • WellerM, CloughesyTF, Perry JR, Wick W. 2013. Standards of care for treatment of recurrent glioblastoma: Are we there yet? Neuro-Oncology 15:4-27
    • (2013) Neuro-Oncology , vol.15 , pp. 4-27
    • Weller, M.1    Cloughesy, T.F.2    Perry, J.R.3    Wick, W.4
  • 145
    • 67650075305 scopus 로고    scopus 로고
    • Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment
    • Pope WB, Kim HJ, Huo J, Alger J, Brown MS, et al. 2009. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-89
    • (2009) Radiology , vol.252 , pp. 182-189
    • Pope, W.B.1    Kim, H.J.2    Huo, J.3    Alger, J.4    Brown, M.S.5
  • 146
    • 80755189369 scopus 로고    scopus 로고
    • Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
    • Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, et al. 2011. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology 13:1151-61
    • (2011) Neuro-Oncology , vol.13 , pp. 1151-1161
    • Ellingson, B.M.1    Cloughesy, T.F.2    Lai, A.3    Mischel, P.S.4    Nghiemphu, P.L.5
  • 147
    • 84863754907 scopus 로고    scopus 로고
    • VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
    • Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. 2012. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21-35
    • (2012) Cancer Cell , vol.22 , pp. 21-35
    • Lu, K.V.1    Chang, J.P.2    Parachoniak, C.A.3    Pandika, M.M.4    Aghi, M.K.5
  • 148
    • 78651408563 scopus 로고    scopus 로고
    • Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape
    • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, et al. 2011. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 71:19-28
    • (2011) Cancer Res. , vol.71 , pp. 19-28
    • Di Tomaso, E.1    Snuderl, M.2    Kamoun, W.S.3    Duda, D.G.4    Auluck, P.K.5
  • 149
    • 68049093213 scopus 로고    scopus 로고
    • Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
    • Lucio-Eterovic AK, Piao Y, de Groot JF. 2009. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15:4589-99
    • (2009) Clin. Cancer Res. , vol.15 , pp. 4589-4599
    • Lucio-Eterovic, A.K.1    Piao, Y.2    De Groot, J.F.3
  • 150
    • 79957927593 scopus 로고    scopus 로고
    • Genetic modeling of gliomas in mice: New tools to tackle old problems
    • Hambardzumyan D, Parada LF, Holland EC, Charest A. 2011. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59:1155-68
    • (2011) Glia , vol.59 , pp. 1155-1168
    • Hambardzumyan, D.1    Parada, L.F.2    Holland, E.C.3    Charest, A.4
  • 151
    • 84856029482 scopus 로고    scopus 로고
    • Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas
    • Munoz DM, Guha A. 2011. Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget 2:590-98
    • (2011) Oncotarget , vol.2 , pp. 590-598
    • Munoz, D.M.1    Guha, A.2
  • 152
    • 62449252775 scopus 로고    scopus 로고
    • Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
    • Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, et al. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. USA 106:2712-16
    • (2009) Proc. Natl. Acad. Sci. USA , vol.106 , pp. 2712-2716
    • Zhu, H.1    Acquaviva, J.2    Ramachandran, P.3    Boskovitz, A.4    Woolfenden, S.5
  • 153
    • 0034020459 scopus 로고    scopus 로고
    • Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
    • Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25:55-57
    • (2000) Nat. Genet. , vol.25 , pp. 55-57
    • Holland, E.C.1    Celestino, J.2    Dai, C.3    Schaefer, L.4    Sawaya, R.E.5    Fuller, G.N.6
  • 155
    • 34147184365 scopus 로고    scopus 로고
    • Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
    • Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, et al. 2007. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 6:1167-74
    • (2007) Mol. Cancer Ther. , vol.6 , pp. 1167-1174
    • Sarkaria, J.N.1    Yang, L.2    Grogan, P.T.3    Kitange, G.J.4    Carlson, B.L.5
  • 156
    • 84873110988 scopus 로고    scopus 로고
    • Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ
    • Joo KM, Kim J, Jin J, Kim M, Seol HJ, et al. 2013. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3:260-73
    • (2013) Cell Rep. , vol.3 , pp. 260-273
    • Joo, K.M.1    Kim, J.2    Jin, J.3    Kim, M.4    Seol, H.J.5
  • 159
    • 84866767773 scopus 로고    scopus 로고
    • Decisionmaking and management of gliomas: Practical considerations
    • Hottinger AF, Homicsko K, Negretti L, Lhermitte B, Stupp R. 2012. Decisionmaking and management of gliomas: practical considerations. Ann. Oncol. 23(Suppl. 10):33-40
    • (2012) Ann. Oncol. , vol.23 , Issue.SUPPL. 10 , pp. 33-40
    • Hottinger, A.F.1    Homicsko, K.2    Negretti, L.3    Lhermitte, B.4    Stupp, R.5
  • 160
    • 84856728163 scopus 로고    scopus 로고
    • Individualized targeted therapy for glioblastoma: Fact or fiction?
    • Weller M, Stupp R, Hegi M, Wick W. 2012. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18:40-44
    • (2012) Cancer J. , vol.18 , pp. 40-44
    • Weller, M.1    Stupp, R.2    Hegi, M.3    Wick, W.4
  • 161
    • 78650029376 scopus 로고    scopus 로고
    • The use of global profiling in biomarker development for gliomas
    • Sulman EP, Aldape K. 2011. The use of global profiling in biomarker development for gliomas. Brain Pathol. 21:88-95
    • (2011) Brain Pathol. , vol.21 , pp. 88-95
    • Sulman, E.P.1    Aldape, K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.